Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.

These medications have changed the prognosis for stage I to stage III HER2-positive breast cancer from poor to good. Herceptin reduces the risk of recurrence and improves 10-year survival rates ...

Background: Variable rates of HER2 protein overexpression ... AOC were centrally screened for HER2 status (243 patients in fi rst line, 77 in relapse). All positive (IHC 3+) and doubtful (IHC ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

Metastatic HER2-positive breast cancer treatment has evolved, with trials like CLEOPATRA and STOP-HER2 indicating potential for long-term survival. Future research ... treatment outcomes and ...

Additionally, seven-year overall survival rates were 89.1% and 84.4% between the two approaches ... for patients with metastatic, HER2-positive breast cancer who had previously been treated with ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment of patients with HER2-positive gastric or gastroesophageal junction ...

DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with ...